iNCOVACC will be the world’s first COVID-19 booster dose. It will give India more options to choose from when it comes to third doses or precautionary doses
View More Bharat Biotech launches nasal vaccine iNCOVACC
Phase III trials (as a 2-dose regimen) were conducted for safety, immunogenicity in ~3100 subjects, in 14 trial sites across India.
View More Bharat Biotech’s Covid Nasal vaccine: Rs 800 in pvt, Rs 325 in govt for iNCOVACC
Bharat Biotech’s Intranasal Vaccine receives both Primary series and Heterologous booster approval from from the Central Drugs Standard Control Organisation (CDSCO). This is first ever…
View More Bharat Biotech’s Covid nasal vaccine gets CDSCO approval
